Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 4/20 | 0.46 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.43 |
| ▸ | PGK1 | P00558 | 1/20 | 0.37 |
| ▸ | PGK2 | P07205 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2295173 | 0.91 | ADORA2A (0.48) | ADORA2AADORA2BADORA3PGK1PGK2 | |
| SCHEMBL1081739 | 0.91 | ADORA2A (0.57) | ADORA2AADORA2BADORA3 | |
| Hydrochloric Acid SCHEMBL6754870 | 0.90 | ADORA2A (0.56) | ADORA2AADORA2BADORA3 | |
| Hydrochloric Acid SCHEMBL2031973 | 0.89 | ADORA2A (0.55) | ADORA2AADORA2BADORA3 | |
| SCHEMBL724838 | 0.88 | ADORA2A (0.47) | ADORA2AADORA2BADORA3 | |
| SCHEMBL5690283 | 0.85 | ADORA2A (0.35) | ADORA2AADORA2BADORA3 | |
| SCHEMBL726188 | 0.82 | ADORA2A (0.46) | ADORA2AADORA2BADORA3 | |
| SCHEMBL5689599 | 0.80 | ADORA2A (0.37) | ADORA2AADORA2BADORA3 | |
| SCHEMBL258936 | 0.78 | LMNA (0.36) | ADORA2AADORA3 | |
| SCHEMBL177666 | 0.76 | HSPA8 (0.44) | ADORA2AADORA2BADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0996453-B1 | METHODS FOR THE INHIBITION OF NEURONAL ACTIVITY BY LOCAL DELIVERY OF ADENOSINE | MOHLER HANNS (CH) | 2004-04-28 | — | — | EP | claimed |
| US-8338411-B2 | Compounds | SANOFI (FR) | 2012-12-25 | — | — | US | disclosed |
| EP-1390349-B1 | AMINOQUINOLINE AND AMINOPYRIDINE DERIVATIVES AND THEIR USE AS ADENOSINE A3 LIGANDS | SANOFI SA (FR) | 2012-07-25 | — | — | EP | disclosed |
| US-8071601-B2 | Aminoquinoline derivatives and their use as adenosine A3 ligands | SANOFI-AVENTIS (FR) | 2011-12-06 | — | — | US | disclosed |
| US-7964731-B2 | Isotopically marked quinoline derivatives as adenosin A3 receptor ligands | SANOFI-AVENTIS (FR) | 2011-06-21 | — | — | US | disclosed |
| US-20110112092-A1 | AMINOQUINOLINE DERIVATIVES AND THEIR USE AS ADENOSINE A3 LIGANDS | SANOFI-AVENTIS (FR) | 2011-05-12 | — | — | US | disclosed |
| EP-2167470-B1 | TRIAZOLO [1, 5-A]QUINOLINES AS ADENOSINE A3 RECEPTOR LIGANDS | SANOFI AVENTIS (FR) | 2011-03-16 | — | — | EP | disclosed |
| US-20110009626-A1 | AMINOQUINOLINE DERIVATIVES AND THEIR USE AS ADENOSINE A3 LIGANDS | SANOFI-AVENTIS (FR) | 2011-01-13 | — | — | US | disclosed |
| US-7799922-B2 | Aminoquinoline derivatives and their use as adenosine A3 ligands | SANOFI-AVENTIS (FR) | 2010-09-21 | — | — | US | disclosed |
| EP-1814857-B1 | ISOTOPICALLY MARKED QUINOLINE DERIVATIVES AS ADENOSIN A3 RECEPTOR LIGANDS | SANOFI AVENTIS (FR) | 2010-09-01 | — | — | EP | disclosed |
| EP-1456204-A1 | TRIAZOLO-QUINOLIN DERIVATIVES USEFUL AS ADENOSINE RECEPTOR LIGANDS | Sanofi-Aventis (FR) | 2004-09-15 | — | — | EP | disclosed |
| EP-1456205-A1 | IMIDAZOQUINOLINE DERIVATIVES | Sanofi-Aventis (FR) | 2004-09-15 | — | — | EP | disclosed |
| EP-0996453-B1 | METHODS FOR THE INHIBITION OF NEURONAL ACTIVITY BY LOCAL DELIVERY OF ADENOSINE | MOHLER HANNS (CH) | 2004-04-28 | — | — | EP | disclosed |
| EP-1390349-A1 | AMINOQUINOLINE AND AMINOPYRIDINE DERIVATIVES AND THEIR USE AS ADENOSINE A3 LIGANDS | Sanofi-Aventis (FR) | 2004-02-25 | — | — | EP | disclosed |
| WO-2003053969-A1 | IMIDAZOQUINOLINE DERIVATIVES | SANOFI-SYNTHELABO (FR) | 2003-07-03 | — | — | WO | disclosed |
| WO-2003053968-A1 | TRIAZOLO-QUINOLIN DERIVATIVES USEFUL AS ADENOSINE RECEPTOR LIGANDS | SANOFI-SYNTHELABO (FR) | 2003-07-03 | — | — | WO | disclosed |
| WO-2002096879-A1 | AMINOQUINOLINE AND AMINOPYRIDINE DERIVATIVES AND THEIR USE AS ADENOSINE A3 LIGANDS | SANOFI-SYNTHELABO (FR) | 2002-12-05 | — | — | WO | disclosed |
| US-6110902-A | IMPLANTING ENCAPSIDATED ADENOSINE RELEASING CELLS TO DELIVER A CONTINUOUS LOCAL DOSE OF ADENOSINE INTO THE BRAIN OF THE PATIENT | MOEHLER HANNS (CH) | 2000-08-29 | — | — | US | disclosed |
| EP-0996453-A1 | METHODS FOR THE INHIBITION OF NEURONAL ACTIVITY BY LOCAL DELIVERY OF ADENOSINE | Mohler, Hanns (CH) | 2000-05-03 | — | — | EP | disclosed |
| WO-1998058653-A1 | METHODS FOR THE INHIBITION OF NEURONAL ACTIVITY BY LOCAL DELIVERY OF ADENOSINE | MOHLER HANNS (CH) | 1998-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112092-A1 | AMINOQUINOLINE DERIVATIVES AND THEIR USE AS ADENOSINE A3 LIGANDS | ADORA3, ADORA2A, ADORA2B | ADORA2A 2/4885ADORA2B 3/4885ADORA3 1/4885 |
| US-20110009626-A1 | AMINOQUINOLINE DERIVATIVES AND THEIR USE AS ADENOSINE A3 LIGANDS | ADORA3, ADORA2A, ADORA2B | ADORA2A 2/4885ADORA2B 3/4885ADORA3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.